Glucagon-like peptide 1 receptor signaling attenuates respiratory syncytial virus-induced type 2 responses and immunopathology

J Allergy Clin Immunol. 2018 Aug;142(2):683-687.e12. doi: 10.1016/j.jaci.2018.01.053. Epub 2018 Apr 17.

Abstract

GLP-1R signaling, an emerging anti-inflammatory therapeutic 59 target, 60 attenuated type 2-associated immunopathology in mice infected with a strain of RSV that was 61 isolated from a hospitalized infant with severe lower respiratory tract infection and bronchiolitis.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cells, Cultured
  • Glucagon-Like Peptide-1 Receptor / agonists
  • Glucagon-Like Peptide-1 Receptor / metabolism*
  • Humans
  • Hypoglycemic Agents / pharmacology
  • Hypoglycemic Agents / therapeutic use*
  • Immunity, Innate
  • Infant
  • Interleukin-13 / metabolism
  • Liraglutide / pharmacology
  • Liraglutide / therapeutic use*
  • Lymphocyte Activation
  • Mice
  • Mice, Inbred BALB C
  • Respiratory Syncytial Virus Infections / immunology*
  • Respiratory Syncytial Viruses / physiology*
  • Signal Transduction
  • Th2 Cells / immunology*
  • Viral Load

Substances

  • Glp1r protein, mouse
  • Glucagon-Like Peptide-1 Receptor
  • Hypoglycemic Agents
  • Interleukin-13
  • Liraglutide